The KwaZulu-Natal Research Institute for TB-HIV (K-RITH) and Africa Centre for Population Health have joined to form an exciting new interdisciplinary research institute, called the Africa Health Research Institute.
The new body aims to become a source of fundamental discoveries into the susceptibility, transmission and cure of HIV and TB and related diseases, seeking always to improve diagnosis, prevention and treatment.
Find out more about their plans in their video interview at http://www.ahri.org/ with incoming Director, Professor Deenan Pillay, and from the press release below:
In a bold move to improve the health of people locally and globally, two research giants in KwaZulu-Natal (KZN) are joining forces to form a ground-breaking new interdisciplinary institute to fight tuberculosis (TB), HIV and related diseases.
The new organisation, the Africa Health Research Institute, is located at the heart of South Africa’s TB and HIV co-epidemic. It combines the renowned Africa Centre for Population Health’s detailed population data from over 100 000 participants, with the KwaZulu-Natal Research Institute for TB-HIV’s (K-RITH’s) basic science, experimental medicine and world-class laboratory facilities.
The new venture is made possible through R1.2-billion in grants from Wellcome Trust and the Howard Hughes Medical Institute (HHMI), with UCL (University College London) and the University of KwaZulu-Natal (UKZN) as significant academic partners.
The Africa Health Research Institute’s interdisciplinary ‘population to laboratory – and back to population’ approach to addressing the TB and HIV co-epidemic comes at a critical moment. Despite advances in antiretroviral therapy and talk of the ‘end of Aids’, HIV and HIV-related TB remain devastating diseases – with TB among the leading causes of death in South Africa. The province of KZN has the highest HIV burden, while TB is responsible for more than 14% of all deaths here. The emergence of drug resistant strains of TB and HIV meanwhile present a major public health crisis.
The Africa Health Research Institute is committed to working towards the elimination of HIV and TB disease. To achieve this, the institute will bring together leading researchers from different fields, use cutting-edge science to improve people’s health, and help to train the next generation of African scientists.
Wellcome Trust and HHMI are two of the largest funders of biomedical research and the establishment of the Africa Health Research Institute represents the first time these organisations have partnered in the global health arena. The complementary strengths of our partner institutions allow a broader scope of interdisciplinary, translational research that is relevant both locally and internationally and is underpinned by strong policy engagement.
“KwaZulu-Natal is at the centre of the dual epidemics of HIV and TB. This is the one place in the world where the marrying of disciplines can have maximum impact on new HIV infections and TB transmission,” said Professor Deenan Pillay, Director of the Africa Centre for Population Health, and incoming Director of the Africa Health Research Institute. “We will link clinical and laboratory-based studies with social science, health systems research and population studies to make fundamental discoveries about these killer diseases, as well as demonstrating how best to reduce morbidity and mortality.”
Our ongoing research areas include:
- the longest running population-based HIV Treatment as Prevention (TasP) trial in Africa
- An innovative research project on human lung granuloma biology, involving close collaboration with surgeons performing lung resections at Durban’s Inkosi Albert Luthuli Central Hospital and King Dinuzulu Hospital Complex
- Applying genomics to better understand TB drug resistance
Our laboratory facilities at the K-RITH Tower Building in Durban include state-of-the-art Biosafety Level 3 (BSL3) labs, which allow scientists to safely work with dangerous airborne diseases such as TB. We are also host to Africa’s only microfluidic chip-making foundry, where scientists are working to develop low-cost, sample-in-answer-out disease diagnostic devices to address the HIV and TB epidemics.
The Africa Health Research Institute’s research is truly collaborative: we work with over 60 academic and clinical institutions in South Africa and elsewhere in Africa and the world.
“UCL takes a collaborative approach to tackling major global challenges and forging successful partnerships is a key priority and strength of the School of Life and Medical Sciences,” said Professor David Lomas, UCL Vice-Provost (Health). “Our commitment to the Africa Health Research Institute builds on our role as one of the world’s leading centres for biomedical research. The Africa Health Research Institute will become a significant global partner for UCL, in line with our Global Engagement Strategy, and will strengthen the translation of our research into new therapies that address the HIV/TB co-epidemic and benefit human health.”
“The investment by Wellcome and others in South African health research has undoubtedly improved the lives of people with HIV over the past 15 years. But growing resistance to HIV and TB treatments, and stubbornly high infection rates, mean we must redouble our efforts if we are going to sustain our hard-won progress,” said Professor Mike Turner, Wellcome Trust Acting Director of Science and Head of Infection Biology. “Long-standing threats such as TB, HIV and increasingly the non-communicable diseases, will only be solved with a strong research base which combines different approaches. Individuals and teams at the Africa Health Research Institute will play a leading role in shaping and driving world class, locally driven and relevant research that improves human health. Ultimately, solutions to health crises will be driven by African scientists and, increasingly, African investment.”
“We believe this new research centre is well positioned to make the critical scientific advances needed to improve our understanding of and advance treatment for these two deadly infectious diseases,” said HHMI President Robert Tjian. “The unification of these institutes makes possible a spectrum of research previously unimagined by either the Africa Centre or K-RITH separately.”
“The unification is a major achievement. It maximises the opportunities for impact of world leading research on the twin epidemics of HIV and TB,” said UKZN spokesperson Lesiba Seshoka.